Avalo Therapeutics, Inc. Research And Development Expense

Quick Answer

Avalo Therapeutics, Inc. reported Research And Development Expense of $5.79 million for the year ending 2018.

  • Avalo Therapeutics, Inc. showed an increase of +32.3% in Research And Development Expense from 2017 to 2018.
  • This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2019.
  • XBRL data for this metric is available from 2013 to 2018 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2013 to 2018), Avalo Therapeutics, Inc.'s Research And Development Expense has declined by 35.1%.
  • Historical annual values: Fiscal year 2018: $5.79 million | Fiscal year 2017: $4.37 million | Fiscal year 2016: $10.15 million | Fiscal year 2015: $6.59 million | Fiscal year 2014: $12.24 million | Fiscal year 2013: $8.91 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: